LOW RD EFFICIENCY IN LARGE PHARMACEUTICAL COMPANIES

Large pharmaceutical companies will face serious challenges in the future when several of their blockbuster drugs run out of patents, and meanwhile a growing political pressure to stop the fast increase in health care expenditures has emerged. The recent wave of mergers and acquisitions (MA) within...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of medical research (New York, N.Y.) Vol. 3; no. 2; pp. 141 - 151
Main Authors Madsen, Erik Strøjer, Wu, Yanqing
Format Journal Article
LanguageEnglish
Published New York Addleton Academic Publishers 01.10.2016
Subjects
Health and medicine and law
Innovations
Medical care, Cost of
Pharmaceutical industry
patents
MA strategy
pharmaceutical RD
drug innovation
company sizeeffects
RD efficiency
Online AccessGet full text

Cover

More Information
Summary:Large pharmaceutical companies will face serious challenges in the future when several of their blockbuster drugs run out of patents, and meanwhile a growing political pressure to stop the fast increase in health care expenditures has emerged. The recent wave of mergers and acquisitions (MA) within the industry can be seen as an effective means to reduce costs and compensate for the reduced earnings from patented drugs. The paper examines the main development in expenditure on research and development (RD) and number of patents in the industry with a focus on the role of company size. The analysis builds on a data set containing information of both patents and RD expenditure from the world’s top 90 largest pharmaceutical companies, as well as their account data from 2002 to 2013. The empirical part estimates the firm size effect on RD efficiency and the amount of investment allocated to RD. Fixed effects estimation models have been applied to control for differences in firm characteristics. We find significantly lower innovation activities in large companies with low innovation productivity as well. The MA strategy of the large pharmaceutical companies may have been their wise move to catch up on new drugs and revenues.
ISSN:2334-4814
2376-4481